




Risk of Developing Hypokalemia in Patients With Hypertension Treated With
Combination Antihypertensive Therapy
Krogager, Maria Lukács; Mortensen, Rikke Nørmark; Lund, Peter Enemark; Bøggild, Henrik;











Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Krogager, M. L., Mortensen, R. N., Lund, P. E., Bøggild, H., Hansen, S. M., Kragholm, K., Aasbjerg, K.,
Søgaard, P., & Torp-Pedersen, C. (2020). Risk of Developing Hypokalemia in Patients With Hypertension
Treated With Combination Antihypertensive Therapy. Hypertension, 75(4), 966-972.
https://doi.org/10.1161/HYPERTENSIONAHA.119.14223
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
966
Current guidelines for the management of hypertension rec-ommend 5 major drug classes, namely calcium channel 
blockers (CCB), ACE (angiotensin-converting enzyme) inhibi-
tors, ARBs (angiotensin receptor blockers), β-blockers, and 
thiazides/thiazide-like diuretics. In patients who do not have 
an optimal response on monotherapy, guidelines recommend 
sequentially adding other antihypertensive drugs until blood 
pressure target is achieved.1
Most of the drugs used for the treatment of hypertension, 
especially thiazide diuretics, ACE inhibitors, and ARBs, are 
known to influence potassium homeostasis through different 
mechanisms.2 In combination therapy, avoidance of potassium 
imbalances can be a challenge and prevention of potassium 
imbalances is important as they can elicit arrhythmias and 
sudden cardiac death.2–5 Moreover, a previous study showed 
that potassium levels outside the interval 4.1 to 4.7 mmol/L 
were associated with increased mortality risk in patients 
with hypertension.6 However, there is little knowledge on the 
occurrence of potassium imbalances in relation to different 
combination therapies.
Using the Danish nationwide administrative registries, 
we investigated the risk of developing hypokalemia within 
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Abstract—Little is known about the occurrence of hypokalemia due to combination therapy for hypertension. Using data 
from Danish administrative registries, we investigated the association between different combinations of antihypertensive 
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matched to a patient with hypokalemia (K, <3.5 mmol/L) on age, sex, renal function, and time between index date 
and date of potassium measurement. Combination therapies were subdivided into 10 groups including β-blockers 
(BB)+thiazides (BB+thiazides), calcium channel blockers (CCB)+renin angiotensin system inhibitors (RASi)+thiazides 
(CCB+RASi+Thiazides), calcium channel blockers+thiazides (CCB+thiazides), and β-blockers+renin angiotensin system 
inhibitors+thiazides (BB+RASi+thiazides). We used conditional logistic regression to estimate the odds of developing 
hypokalemia for different combinations of antihypertensive drugs within 90 days of combination therapy initiation. We 
matched 463 patients with hypokalemia to 926 patients with normal potassium concentrations. The multivariable analysis 
showed 5.82× increased odds of developing hypokalemia if administered CCB+thiazides (95% CI, 3.06–11.08) compared 
with CCB+RASi. Other combinations significantly associated with increased hypokalemia odds were BB+thiazides (odds 
ratio, 3.34 [95% CI, 1.67–6.66]), CCB+RASi+thiazides (odds ratio, 3.07 [95% CI, 1.72–5.46]), and BB+RASi+thiazides 
(odds ratio, 2.78 [95% CI, 1.41–5.47]). Combinations of thiazides with CCB, RASi, or BB were strongly associated with 
increased hypokalemia risk within 90 days of treatment initiation.  (Hypertension. 2020;75:966-972. DOI: 10.1161/
HYPERTENSIONAHA.119.14223.) • Online Data Supplement
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Denmark: http://www.dst.dk/en/OmDS/organisation/TelefonbogOrg.
aspx?kontor=13&tlfbogsort=sektion or the Danish Data Protection 
Agency: https://www.datatilsynet.dk/english/the-danish-data-pro-
tection-agency/contact/. More information regarding data access is 
available at https://www.dst.dk/en/TilSalg/Forskningsservice.
Databases
All residents in Denmark have a personal, unique, and permanent 
civil registration number that enables linkage of data between all na-
tionwide administrative registries.
We used The Danish Civil Registration System7 to collect data re-
garding age and gender. From The Danish National Patient Registry,8 
we obtained information about hospital admission dates, hospital dis-
charge dates, discharge diagnoses, dates of operation, and procedure 
codes. Diagnoses are classified as primary and secondary according 
to World Health Organization International Classification of Disease. 
From 1994 and onwards the International Classification of Disease, 
Tenth Revision was in use. The Danish National Patient Registry cov-
ers information from 1978 until present time.
From The Danish National Prescription Registry,9 information 
on each individual’s drug redemption was collected. This regis-
ter includes all dispensed prescriptions from all Danish pharmacies 
since 1995 based on the Anatomic Therapeutic Chemical system. 
The Danish healthcare system is state-financed and partly reimburses 
drug costs. For this reason, all Danish pharmacies are required by law 
to register all dispensed drug prescriptions, providing a complete o-
verview of all prescriptions. From 1995, registries of laboratory data 
contain blood test results from 3 of the 5 regions in Denmark, cover-
ing ≈ 4 058 000 inhabitants.
Study Population and Design
Hypertension was defined as the redemption of at least 2 antihyper-
tensive drugs in 2 consecutive quarters. Patients entered the study 
after the first occurrence of redeeming prescriptions for combina-
tion antihypertensive therapy in 2 subsequent quarters.10 This time 
was referred to as the index date. Anatomic Therapeutic Chemical 
codes of the drugs used to define patients as having hypertension 
were included in Table S1 in the online-only Data Supplement. We 
defined hypertension as redemption of at least 2 antihypertensive 
drugs in at least 2 consecutive quarters for different reasons. First, 
by using Danish registries, it was difficult to ascertain whether 
patients were treated for hypertension with monotherapy only. The 
majority of the drugs used to treat high blood pressure can be used 
for other cardiovascular diseases, such as atrial fibrillation, heart 
failure, or myocardial infarction. Second, by using diagnosis code 
approach to identify patients with hypertension, we would have 
lost a considerable sample of patients as in many cases treatment 
and monitoring takes place in a primary care setting. In a study by 
Olesen et al,10 this definition of hypertension was validated and 
the authors found that the positive predictive value of treatment 
with 2 classes of antihypertensive drugs was 80% and the speci-
ficity 94.7%.
The first potassium measurement within 90 days from index date 
was kept methods for blood potassium analysis have not been simi-
lar in all laboratories over the entire study period, having measured 
both serum and plasma potassium concentrations. As the normal 
ranges for the 2 methods of measuring blood potassium concentra-
tions do not differ substantially, we referred to all measurements as 
serum potassium.
Exclusion criterias were age below 18 years, no potassium meas-
urement up to 30 days before index date, hypokalemia, or hyper-
kalemia up to 30 days before index date, hyperkalemia at the first 
potassium measurement after combination therapy initiation and pre-
scription of loop diuretics. The population flow chart with inclusion 
and exclusion criteria was shown in Figure S1.
This study used a nested case-control design. Using incidence 
density matching, 2 patients without hypokalemia (K, >3.5 mmol/L; 
n=926) were matched to each patient with hypokalemia (K, <3.5 
mmol/L; n=463) on age, sex, renal function, and time between index 
date and date of potassium measurement.
Comorbidities, Procedures, and Concomitant 
Medication
The following discharge diagnoses present before index date were 
assessed to characterize the population: heart failure, ischemic heart 
disease, acute myocardial infarction, atrial fibrillation, atrial flutter, 
second- or third-degree atrioventricular block, ventricular tachy-
cardia or fibrillation, stroke, chronic obstructive pulmonary disease, 
chronic liver disease, inflammatory bowel disease, diabetes mellitus, 
hypothyroidism, cancer, and stroke. None of the patients had a his-
tory of diabetes insipidus, syndrome of inappropriate antidiuretic 
hormone secretion, primary hyperaldosteronism, or Addison disease.
The kidney function of each patient was assessed by calculating 
the estimated glomerular filtration rate (eGFR),11 and an eGFR <30 
mL/(min·1.73 m2) suggested renal insufficiency. This cutoff level 
was chosen, as we did not have information on whether patients had 
evidence of kidney damage (ie, albuminuria, hematuria, structural 
changes, or biopsy verification). Serum creatinine used to calculate 
eGFR was obtained within 7 days before potassium measurement, 
and patients with missing creatinine values were excluded.
From the Danish National Prescription Registry, we identified 
the following redeemed medication known to be associated with 
potassium disturbances: potassium supplements, antimicrobials, 
β2-agonists, mineralo- and glucocorticoids, laxatives, xanthines, 
and macrolides. Only potassium supplementation, antimicrobials, 
and β2-agonists were present in the nested case-control population. 
Potassium supplements were supplements as a single pill therapy 
combined with an antihypertensive (Anatomic Therapeutic Chemical 
C03) or as an individual pill (ATC A12B). Definitions of comorbidi-
ties and concomitant medication before index date were illustrated 
in Table S2.
Statistical Analyses
Categorical variables were reported as counts and percentages and 
continuous variables as medians with 25th to 75th percentiles. 
Differences between variables were compared using χ2 and Kruskal-
Wallis tests, as appropriate.
An incident episode of hypokalemia was defined as a blood potas-
sium level <3.5 mmol/L within 90 days from index date.
Cumulative incidence proportion curves for developing hypoka-
lemia in patients treated with combination antihypertensive therapy, 
who had available potassium measurements within 90 days from in-
dex date and no potassium imbalances up to 30 days before index 
date, were estimated.
The independent variable defining the different possible combina-
tions of antihypertensive treatment was coded as a dummy variable 
with the 10 most frequent possibilities identified in the population:
1. BB (β-blockers)+CCB
2. BB+RASi (renin-angiotensin system inhibitors)








Antihypertensive drug groups 1, 6, 7, and 8 referred to combinations 
of CCBs with other blood pressure drugs. However, these groups only 
contain one type of CCBs, namely dihydropyridine derivatives, such 
as amlodipine. Conditional logistic regression analysis was used to 
estimate the odds ratio and 95% CI between different combination 
therapies and developing hypokalemia with CCB+RASi as reference.
When investigating the association between hypokalemia and the 
10 antihypertensive drug groups the model was adjusted for initial se-
rum sodium, malignancy, inflammatory bowel disease, diabetes mel-
litus, and chronic liver disease.
As some of the antihypertensive drug combinations can also indi-
cate cardiovascular diagnoses other than hypertension, we performed 
a sensitivity analysis where we also matched the controls on history 
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A 2-Sided P Value <0.05 was considered statistically significant 
since not every patient with hypertension, treated with combination 
therapy, had a potassium measurement available within 90 days from 
treatment initiation, we also looked at the prevalence of different co-
morbidities between our population and the general population with 
no potassium concentrations within the predefined timeline.
Data management and analyses were performed using SAS, ver-
sion 9.4 (SAS Institute, Inc, Cary, NC) and R, version 3.5.1 (R Core 
Team [2018]). R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria; https://
www.R-project.org/.
Ethics
The Danish Data Protection Agency approved the use of data (ref-
erence: 2007-58-0015, internal reference: GEH-2014-015, I-Suite 




Population characteristics of the cohort, from which cases and 
controls were identified and matched on different variables, 
were illustrated in Table S3. During 1995 to 2018, 11 896 
patients treated for hypertension with combination therapies 
had a potassium measurement within 90 days of index date. 
Among the patients, 3.9% had potassium concentrations 
below 3.5 mmol/L. Furthermore, we observed that 48.5% of 
the patients redeemed thiazides, of which 1.6% were thiazide-
like diuretics and 45% hydrochlorothiazides. Additionally, 
31.8% of the population was prescribed potassium supple-
ments, of which 86.7% represented potassium chloride as 
single pill combined with an antihypertensive.
After matching on age, sex, eGFR, renal insufficiency, 
and time from index date to potassium measurement, we 
ended up with 463 cases and 926 controls. Median time 
from index date to potassium measurement was 30 days 
(0, 90). Following proportions were observed in each of 
the 10 combination antihypertensive therapies: BB+CCB 
4.3%, BB+RASi 16.9%, BB+RASi+mineral receptor an-
tagonist 3.2%, BB+RASi+thiazides 4.0%, BB+thiazides 
4.4%, CCB+RASi 12.5%, CCB+RASi+thiazides 6.5%, 
CCB+thiazides 6.7%, RASi+thiazides 12.2%, and Other 
combinations 12.2% (Table).
We also observed higher prevalence of hypoka-
lemia in patients redeeming CCB+thiazides (12.1%) and 
RASi+thiazides (30.7%) than in patients treated with any of 
the other drug groups. Among the cases (with hypokalemia), 
45.8% redeemed potassium supplement.
Antihypertensive Combination Therapies and Risk 
of Hypokalemia
Figure S2 illustrated the cumulative incidence proportion of 
hypokalemia in patients treated with combination antihyper-
tensive therapy who had available potassium measurements 
within 90 days of the index date and no potassium imbalances 
up to 30 days before index date (n=11 896). After stratifying 
on the 10 combination therapies the cumulative incidence 
curves showed that the combination of CCB+thiazides had a 
significantly higher incidence of hypokalemia than the other 
groups (about 10%; Figure S3).
In the nested case-control population the adjusted con-
ditional logistic regression analysis with CCB+RASi as 
reference showed 5.82× increased odds for development 
of hypokalemia if administered CCB+thiazides (95% CI, 
3.06–11.08). Moreover, patients on BB+thiazides had an odds 
ratio of 3.34 for developing hypokalemia (95% CI, 1.67–
6.66). Other drug combinations significantly associated with 
increased hypokalemia risk were CCB+RASi+thiazides (odds 
ratio, 3.07 [95% CI, 1.72–5.46]) and BB+RASi+thiazides 
(odds ratio, 2.78 [95% CI, 1.41–5.47]; Figure). The univari-
able analysis showed similar results (Figure S4).
Sensitivity Analyses
We performed an additional conditional logistic regression 
analysis on a population matched on age, sex, eGFR, renal in-
sufficiency, time from index date to potassium measurement, 
heart failure, and ischemic heart disease/myocardial infarc-
tion. The results were similar to the main analyses, though 
with slightly lower effect sizes (Figure S5 and Figure S6).
We also looked at differences in comorbidity proportions 
in our nested case-control population versus general popula-
tion treated with combination antihypertensive therapy who 
did not have available serum potassium measurements within 
90 days from index date. We observed that nearly all comor-
bidities had higher rates in the nested case-control population 
than in the general population. See Table S4 and the Table for 
general population demographics.
Discussion
The main findings in this article were (1) hypokalemia among 
patients treated with combination antihypertensive thera-
pies was common, (2) the 3 antihypertensive drug combina-
tions with the highest odds of developing hypokalemia were 
CCB+thiazides, BB+thiazides, CCB+RASi+thiazides.
Current guidelines recommend combination antihyperten-
sive drug treatment strategies in patients not achieving targeted 
blood pressure.1 Pharmacologically, the great majority of the 
patients in this study were treated with combination therapies 
with opposite effects on potassium homeostasis. Despite this 
approach, the occurrence of hypokalemia remained high con-
sidering the short study period. A large scale Swedish study 
investigating determinants of hyperkalemia and hypokalemia 
showed that patients with hypertension had 1.80 and 1.05× 
higher odds of developing hypokalemia and hyperkalemia 
within 3 years, respectively.12 This is in line with our find-
ings where we observed increased odds of hypokalemia re-
lated to some specific antihypertensive combination therapies. 
Yet, the 2 studies are not utterly comparable as we both had 
different approaches for defining hypertension (International 
Classification of Disease codes versus 2 concomitant antihy-
pertensive drugs) and different aims.
Comparison of our findings with other studies was difficult, 
as the great majority of previous articles focused on outcomes 
like stroke and cardiovascular events1 instead of dyskalemias. 
We found that CCB+thiazides, CCB+RASi+thiazides, and 
BB+thiazides were highly associated with increased risk of 
hypokalemia when compared with CCB+RASi. In the follow-
ing paragraphs, each of the drug combinations and their asso-
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CCB+Thiazides
A meta-analysis based on the results of 4 randomized trials 
investigated the efficacy and safety of CCBs and thiazide 
(-like) diuretics. The authors observed that the most frequent 
adverse event related to CCB+diuretic combination was 
hypokalemia.13 Because of the insufficient knowledge about 
dyskalemias caused by CCB+thiazides, we searched liter-
ature treating the 2 drugs individually. There is little recent 
knowledge on the effect of CCB on potassium homeostasis 
either in large or small-scale studies. On one hand, numerous 
Table. Demographics of the Matched Population
Controls (n=926) Cases (n=463) Total (n=1389) P Value
Sex
  Female 484 (52.3)* 242 (52.3)* 726 (52.3)* 1.0*
Age, median (range) 65.0 (21.0–95.0)* 66.0 (23.0–95.0)* 65.0 (21.0–95.0)* 0.55*
Days from hypertension to potassium 
measurement, median (range)
30.0 (0.0–90.0)* 31.0 (0.0–90.0)* 30.0 (0.0–90.0)* 0.68*
Serum sodium, median (range) 140.0 (113.0–146.0)* 140.0 (118.0–148.0)* 140.0 (113.0–148.0)* 0.15*
Renal insufficiency 10 (1.1)* 5 (1.1)* 15 (1.1)* 1.0*
eGFR, median (range) 77.0 (10.0–214.0) 79.0 (7.0–222.0) 78.0 (7.0–222.0) 0.32
Treatment combinations
  BB+CCB 41 (4.4) 19 (4.1) 60 (4.3)  
  BB+RASi 195 (21.1) 40 (8.6) 235 (16.9)  
  BB+RASi+MRA 40 (4.3) 4 (0.9) 44 (3.2)  
  BB+RASi+thiazides 33 (3.6) 23 (5.0) 56 (4.0)  
  BB+thiazides 32 (3.5) 29 (6.3) 61 (4.4)  
  CCB+RASi 134 (14.5) 40 (8.6) 174 (12.5)  
  CCB+RASi+thiazides 49 (5.3) 42 (9.1) 91 (6.6)  
  CCB+thiazides 37 (4.0) 56 (12.1) 93 (6.7)  
  RASi+thiazides 264 (28.5) 142 (30.7) 406 (29.2)  
  Other combinations 101 (10.9) 68 (14.7) 169 (12.2) < 0.0001
Heart failure 153 (16.5) 30 (6.5) 183 (13.2) < 0.0001
IHD/MI 224 (24.2) 68 (14.7) 292 (21.0) < 0.0001
COPD 56 (6.0) 30 (6.5) 86 (6.2) 0.84
Diabetes mellitus 121 (13.1) 41 (8.9) 162 (11.7) 0.03
Chronic liver disease 24 (2.6) 9 (1.9) 33 (2.4) 0.57
Hemodialysis ≤3 ≤3 ≤6 …
Malignancy 115 (12.4) 73 (15.8) 188 (13.5) 0.10
Stroke 83 (9.0) 55 (11.9) 138 (9.9) 0.11
Atrial flutter/fibrillation 120 (13.0) 41 (8.9) 161 (11.6) 0.03
Atrioventricular block 13 (1.4) ≤3 ≤16 …
VT/VF 36 (3.9) 13 (2.8) 49 (3.5) 0.38
Inflammatory bowel disease 16 (1.7) 11 (2.4) 27 (1.9) 0.54
Hypothyroidism 18 (1.9) 9 (1.9) 27 (1.9) 1.0
Potassium supplement 312 (33.7) 212 (45.8) 524 (37.7) < 0.0001
Antimicrobials ≤3 ≤3 ≤6 …
β-2 agonists ≤3 ≤3 ≤6 …
Potassium supplement addressed supplementation as a single pill therapy with an antihypertensive and as an individual pill. We attribute 
<=3 to variables with values between 1 and 3 to secure anonymity and protection of personal data. BB indicates β-blockers; CCB, calcium 
channel blockers; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-
defibrillator; IHD/MI, ischemic heart disease/myocardial infarction; MRA, mineral receptor antagonist; RASi, renin-angiotensin system 
inhibitors; and VT/VF, ventricular tachycardia/ventricular fibrillation.
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in vitro, in vivo and case report publications reported hyper-
kalemia following initiation of CCB.14–19 On the contrary, case 
studies and studies on rats showed hypokalemia in relation 
to administration of CCB.20–25 As for thiazide diuretics, nu-
merous studies showed that monotherapy is associated with 
development of hypokalemia.26–28 The mechanisms through 
which the 2 drug types lead to hypokalemia seemed to be very 
different: thiazides enhance renal potassium disposal, while 
CCBs augment extrarenal loss of potassium.21,29–31 However, 
the mechanisms through which CCB can cause both hypo- 
and hyperkalemia are poorly elucidated.
CCB+RASi+Thiazides
No study directly compared the risk of hypokalemia related 
to this combination therapy in relation to other combination 
therapies. Most studies compare the risk of hypokalemia in 
patients treated with thiazides alone versus different combina-
tions of antihypertensive drugs with complementary effect on 
potassium homeostasis.32
BB+Thiazides
The combination of BB and thiazides is no longer first-line 
treatment of arterial hypertension but certainly an effective 
combination in prevention of adverse cardiovascular events.1 
To our knowledge, no study reported increased hypokalemia 
risk in patients prescribed BB+thiazides. Although we do 
know that use of thiazides diuretics can lead to hypokalemia,33 
while use of some BB is associated with increased hyperka-
lemia risk especially in patients with renal dysfunction and 
insulin insufficiency.33
Our results suggested that high odds of hypokalemia 
were strongly related to the use of thiazides as they were pre-
sent in each of the combination therapy groups with signif-
icant increased odds of low potassium concentrations. This 
adverse effect was also observed in patients administered po-
tassium supplements.
Should we be concerned about hypokalemia? Both hypo-
kalemia and hyperkalemia have previously been shown to be 
associated with increased risk of all-cause mortality6,34,35 and 
cardiovascular disease36 in different populations with heart di-
sease. Regarding patients with hypertension, current studies 
have discrepant results. In a previous study, we found that po-
tassium concentrations outside the interval 4.1 to 4.7 mmol/L 
were associated with increased mortality risk.6 Contrarily, 
Franse et al37 found no significant difference in the relative risk 
of all-cause mortality for participants who received low-dose 
chlorthalidone and who experienced hypokalemia compared 
with placebo group. Additionally, Alderman et al38 observed a 
higher all-cause mortality (hazard ratio, 1.21) in patients with 
hypokalemia than in normokalemics. However, the authors 
also found heterogeneity in hazard ratios across the 3 treatment 
arms (chlorthalidone, amlodipine, and lisinopril). Comparison 
of the 3 studies is difficult as the only common features were 
that patients were treated for hypertension and had their blood 
potassium measured. Yet, there are 2 very essential differences 
in these studies that could explain the discrepancy in results, 
namely the burden of disease. First, in our large epidemiolog-
ical study, we included patients who redeemed at least 2 con-
comitant antihypertensive drugs,6 while the randomized trials 
either compare monotherapy with placebo or monotherpies 
within themselves. Undoubtely, patients included in the epi-
demiological study had more advanced hypertension that the 
patients in the randomized trials.
Second, the time when mortality was assessed could be 
a strong influencer of the results. The randomized trials used 
year-1 potassium measurement to investigate long-term mor-
tality (y), while we examined the effect of different potassium 
concentrations measured within 90 days from combination 
antihypertensive therapy on 90 days all-cause mortality.6,37,38 
Ultimately, we believe that hypokalemia is an important risk 
factor or risk marker of cardiovascular disease and mortality. 
Yet, further studies are needed to explain which patients are at 
high risk of adverse effects after an episode of hypokalemia.
Limitations
Most of the limitation were related to the observational nature 
of the study design meaning that unmeasured confounding 
such as vomiting, diarrhea, and diet may affect our findings. 
Information on the clinical indication for blood tests or symp-
toms of dyskalemias and electrocardiographic changes were 
not available. However, according to guidelines patients with 
hypertension need to have their blood pressure monitored 
and standard blood test performed within 3 to 6 months of 
treatment initiation. Therefore, we believe that cases where 
clinicians specifically test for potassium imbalances in our 
population are negligible.
Furthermore, due to the short follow-up time, it was diffi-
cult to calculate dosage of redeemed antihypertensive drugs. 
Figure. Forestplot of multivariable conditional 
logistic regression analysis for the development 
of hypokalemia. Population matched on age, 
sex, renal insufficiency, and time index date 
initiation to serum potassium measurement. 
The model was adjusted for serum sodium, 
renal insufficiency, malignancy,  inflammatory 
bowel disease, diabetes mellitus, alcoholism, 
and chronic liver disease. The combination 
of calcium channel blockers with renin-
angiotensin system inhibitors was used as 
reference. BB indicates β-blockers; CCB, 
calcium channel blockers; MRA, mineral 
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Therefore, compliance issues or overdose could not be identi-
fied for any of the drug groups, which can lead to nondifferen-
tial misclassification.
Finally, the fact that potassium concentrations were meas-
ured in both serum and plasma within the different laborato-
ries over the years is an inevitable limitation, due to cases with 
misclassification of the patients. Reference ranges for normal 
serum potassium and plasma potassium concentrations do not 
differ substantially. The Nordic Reference Interval Project 
recommends that an interval of 3.6 to 4.6 mmol/L is consid-
ered to be normal for serum potassium, whereas an interval 
of 3.5 to 4.4 mmol/L is suggested to be normal for plasma 
potassium.39 False-positive hyperkalemia was presumably 
uncommon as all laboratories left out reporting of potassium 
values in presence of hemolysis.
Conclusions
Combinations of thiazide diuretics with CCB, RASi, or BB 
were strongly associated with increased hypokalemia risk 
within 90 days of treatment initiation, regardless of potassium 
supplementation.
Perspectives
Focus on optimal management of hypertension in clinical 
practice is emphasized in the current practice due to the 
numerous studies showing benefits both related to the risk 
of death but also to cardiovascular comorbidity and health-
related quality of life.40,41 Hypo- and hyperkalemia are com-
mon side effects of the drugs used to treat hypertension. 
Awareness of the risk factors associated with potassium 
disturbances is important to identify patients at risk. For 
example, our study strongly suggested that patients treated 
with CCB+thiazides had an increased probability of devel-
oping hypokalemia within 90 days from index date, despite 
potassium supplementation. Therefore, it would be prudent 
to recommend identifying and closely monitoring patients 
at high risk of potassium imbalances as important goals in 
everyday clinical settings.
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What Is New?
•	Patients treated with thiazide diuretics in combination with calcium 
antagonists, β-blockers, or renin-angiotensin system inhibitors had an 
increased hypokalemia risk within 90 days from combination therapy 
initiation.
•	 Increased hypokalemia risk was observed also in patients administered 
potassium supplements.
What Is Relevant?
•	 Increased hypokalemia risk was present despite all patients being treat-
ed with combination of antihypertensive drugs with opposite effect on 
potassium homeostasis and despite supplementation with potassium in 
some of the cases.
•	 Low potassium concentrations have previously been associated with 
arrhythmogenesis and increased mortality risk in patients with hyper-
tension.
Summary
In this register study comprising 463 patients with hypokalemia 
and 926 patients with normal potassium concentrations, we ob-
served that combination of thiazides with β-blockers, calcium 
channel blockers, and renin-angiotensin system inhibitors had 
increased hypokalemia risk compared with the combination of cal-
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